Novartis to pay Monte Rosa $150 million upfront to develop a new class of drugs
Swiss pharmaceutical giant Novartis will pay Monte Rosa Therapeutics $150 million upfront payment for a global license to develop, manufacture and sell some drug candidates, the U.S.-based biotech firm said on Monday.
NVS vs. LLY: Which Stock Is the Better Value Option?
Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Novartis (NVS) and Eli Lilly (LLY). But which of these two stocks is more attractive to value investors?
What To Expect When Novartis Reports Q3 2024 Results
Novartis will report Q3 results next week and I expect the company to beat EPS and revenue estimates, and increase the full-year revenue and core operating income guidance. Key growth products should drive high single-digit revenue growth in the third quarter. Recent litigation updates on Entresto were negative and Novartis continues to anticipate a 2H 2025 generic launch.
Stay Ahead of the Game With Novartis (NVS) Q3 Earnings: Wall Street's Insights on Key Metrics
Get a deeper insight into the potential performance of Novartis (NVS) for the quarter ended September 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Novartis Gets CHMP Recommendation for Kisqali in Broader Population
The Committee for Medicinal Products for Human Use adopted a positive opinion for NVS' Kisqali to help reduce the risk of recurrence in people with HR+/HER2- early breast cancer.
Novartis (NVS) Upgraded to Buy: Here's Why
Novartis (NVS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here's Why Novartis (NVS) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Swiss competition authority closes Novartis probe without consequences
Switzerland's COMCO competition commission terminated an investigation against Novartis into possibly using blocking patents, without consequences, it said on Thursday.
NVS or LLY: Which Is the Better Value Stock Right Now?
Investors interested in Large Cap Pharmaceuticals stocks are likely familiar with Novartis (NVS) and Eli Lilly (LLY). But which of these two companies is the best option for those looking for undervalued stocks?
Novartis: Value Continues To Build With Double-Digit Percentage Growth Products
Kesimpta continues to do well as a self-administered drug for the treatment of patients with relapsing multiple sclerosis; Q2 2024 sales of $799 million, which is growth of 65% YOY. Pluvicto, as a treatment option for patients with metastatic castration-resistant prostate cancer, has been able to generate Q2 of 2024 sales of $345 million which is growth of 44% YOY. With the FDA accepting the regulatory submission of Scemblix, there is a chance to expand the label to target 1st-line chronic myeloid leukemia patients.
Novartis: Best Performing Big Pharma Of Past 6 Months Still Looks A Solid Long-Term Bet
Novartis shares have risen over 20% in the past 6 months, making it the best-performing global pharmaceutical stock, with strong profitability and manageable debt. Despite some declining revenues from established brands, Novartis' pipeline and recent performance suggest continued growth, with double-digit revenue and income growth expected in 2024. The company lacks a "mega-blockbuster" drug but has a solid portfolio and potential for strategic acquisitions to enhance its pipeline.
